Dr. XU Ting returned to China in 2008 and founded Suzhou Alphamab to work on R&D of biologics. He also co-founded several biotech companies from 2011 to 2015. In 2015, Dr. Xu led the spin-out of Alphamab Oncology and then Initial Public Listing (IPO) on the Main Board of the Hong Kong Stock Exchange (stock code: 9966.HK) in 2019. Prior to Alphamab, Dr. Xu held R&D positions in Archemix, Serono and Biogen, where he had been involved in the development of recombinant therapeutics with several launched products.
Dr. Xu has more than 20 years of innovative R&D experience in the biopharmaceutical industry. Dr. Xu had made significant contributions to the evolving of biosimilar industry in China. Through collaboration, he led the development of more than 30 biosimilar drugs, including Bevacizumab (QILU), Recombinant Factor VIII (CTTQ), hCG (Livzon), TSH (SmartNuclide), and Pertuzumab (CTTQ). Dr. Xu invented Envafolimab, the first subcutaneous (subQ) injectable PD-L1 antibody launched in 2021, and more than 10 clinical-stage biologics, potentially FIC or BIC. He also led the establishment of cutting-edge platforms, such as single-domain antibody (sdAb), bispecific antibody, glycan conjugation for antibody-drug conjugate (ADC), dual payload ADC and high-concentration formulation. Dr. Xu’s focus is to develop the multifunctional antibodies and protein drugs with better precision, lower toxicity, and superior efficacy.
Dr. Xu holds a B.S. in Biochemistry from Nanjing University and a Ph.D. from the Chinese Academy of Science. Currently, Dr. Xu holds adjunct professorship in the Shanghai Institute of Materia Medica, the Chinese Academy of Sciences, Nanjing University and Southeast University. He has led 5 national-level projects such as the "Major New Drug Development" special project.
Dr. Xu has received numerous awards including “Major National Talent Programs”, “Suzhou Science and Technology Innovation and Entrepreneurship Mayor Award", "Suzhou Outstanding Talent Award", "Top Ten Scientific and Technological Innovation and Entrepreneurship Figures in Jiangsu" and so on.
Ms. LIU Yang has nearly 30 years of experience in the biotech industry. Prior to Alphamab Oncology, she served as Vice President of Corporate Operations at Dingfu Biotarget, a biotech company focused on Immuno-Oncology. Ms. Liu also has extensive experience in R&D of antibody drug conjugation.
Ms. Liu has overseen corporate operations, including human resources, supply chain, engineering, internal control and audit, and public relations. She played a pivotal role in building the company’s current team from the ground up, supporting discovery, CMC and clinical development of innovative biologics.
Ms. Liu also led the establishment of highly efficient systems across finance, sourcing and procurement, auditing, and compliance. She is committed to fostering a corporate culture rooted in integrity, support and dedication, championing diversity and advancing women’s leadership at all levels of management. In recent years, Ms. Liu has assumed broader accountability for shaping and executing both immediate and long-term corporate strategies.
Mr. CHO Man is a senior economist. From June 2013 to June 2023, Mr. Cho served as an executive director and the president of Shanghai Pharmaceuticals Holding Co., Ltd. and held directorships in certain of its subsidiaries. From September 2020 to September 2024, he served as the chairman of Shanghai Biomedical Industrial Equity Investment Fund Partnership.
Mr. Cho previously held management positions such as chairman and general manager of Wing Fat Printing Co., Ltd., China Resources Pharmaceutical Group Limited, Sanjiu Enterprise Group, etc.
Mr. Cho obtained a bachelor’s degree in pharmacy from Sichuan University (former West China University of Medical Science) and a master’s degree in management from the School of Management of Fudan University.
Ms. WONG Yan Ki has 30 years of experience in accounting, auditing, corporate finance and capital market. Since November 2007, Ms. Wong has been an executive director of Advanced Capital Limited, where she is responsible for operation management and major decisions. Currently, she is an independent non-executive director in Betta Pharmaceuticals Co., Ltd., and two listed companies in the energy industry.
Ms. Wong previously held senior management positions including CFO and vice president of Great East Packaging Holdings Limited, Benefit Capital Limited, Shengda (Group) Holdings Ltd., etc. Ms. Wong also served as director or chairlady of the board of various public companies listed in different regions, such as Singapore, Hongkong and Nasdaq stock exchanges.
Ms. Wong obtained a bachelor of economics in international accounting from Xiamen University and an executive master degree of business administration from Cheung Kong Graduate School of Business. She has been admitted as a fellow member of several professional accounting associations in the UK, Hong Kong, Australia and other regions.
Dr. GAO Xiang is a veteran in China’s biotech industry with decades of experience bridging the realms of biotech entrepreneurship and corporate governance. He founded GemPharmatech Co., Ltd. in December 2017 and has been serving as its chairman since then. Dr. Gao has been a professor at Nanjing University since 2000, and director of the National Resource Center for Mutant Mice since 2002.
Dr. Gao previously held key research positions such as director of Model Animal Research Center and dean of the Nanjing Biomedical Research Institute of Nanjing University. Dr. Gao has led numerous national research projects and his outstanding contributions to scientific research have been recognized with prestigious awards including the National Science Fund for Distinguished Young Scholars and the Special Prize of the Ministry of Education Award for Scientific and Technological Progress.
Dr. Gao obtained a bachelor’s degree in zoology and a master’s degree in biochemistry from Nanjing University, and a Ph.D. in developmental biology and anatomy from Thomas Jefferson University. He successively conducted his postdoctoral research in Roche Institute of Molecular and The Jackson Laboratory in the United States.
Mr. WU Dong is a venture partner at 6 Dimensions Capital. Mr. Wu worked for Johnson & Johnson for over 10 years and served different positions including the head of Asia Pacific Innovation Center, a vice president of global engineering and emerging market research and development, the Emerging Market Innovation Centre Leader, a vice president of Research Development & Engineering, Asia Pacific and a senior director of emerging market research and development. Mr. Wu is currently the founder and an executive director of Shanghai Jiuben Technology Co., Ltd.
Mr. Wu received his bachelor’s degree in applied chemistry from Fudan University and an executive Master of Business Administration from China-Europe International Business School.
